Skip to main content
Resources › Psychotropics A-Z › Mianserin | Lerivon | Lerivon
Tetracyclic Antidepressant

Mianserin | Lerivon

Clinical Overview

Mianserin is a tetracyclic antidepressant indicated for the treatment of depression and anxiety disorders. Important Note: This medication is not available in the United States but is prescribed in various countries including the UK, Australia, and parts of Europe as an alternative to tricyclic antidepressants with fewer anticholinergic side effects.

Primary Clinical Applications

Mianserin is indicated for depression, particularly in patients who cannot tolerate tricyclic antidepressants or SSRIs. It is also used for anxiety disorders and sometimes for insomnia due to its sedating properties. The medication is particularly valued in elderly patients due to its lower anticholinergic burden.

Mechanism and Clinical Benefits

Mianserin blocks α2-adrenergic autoreceptors, increasing norepinephrine release, and antagonizes various serotonin receptors (5-HT2A, 5-HT2C, 5-HT3) and histamine H1 receptors. This mechanism provides antidepressant effects with sedation and appetite stimulation but fewer anticholinergic effects than tricyclics.

Safety Considerations

While generally well-tolerated, mianserin requires monitoring for blood dyscrasias, particularly agranulocytosis, especially in elderly patients. It has a lower risk of cardiotoxicity compared to tricyclic antidepressants but still requires careful monitoring in overdose situations.

Prescribing Information

Dosing & Administration

Depression – Adults:

  • Initial: 30-40 mg daily, preferably at bedtime
  • Maintenance: 30-90 mg daily
  • Severe depression: Up to 90 mg daily

Elderly:

  • Initial: 10-20 mg daily at bedtime
  • Maintenance: 20-30 mg daily
  • Maximum: 30 mg daily

Administration:

  • Preferably at bedtime due to sedating effects
  • Can be given as single dose or divided doses

Indications

  • Depression
  • Anxiety disorders
  • Off-label: Insomnia, appetite stimulation

Contraindications

  • MAOI use within 14 days
  • Known hypersensitivity to mianserin
  • Acute alcohol intoxication
  • Severe liver disease
  • Blood disorders or history of blood dyscrasias

Warnings & Precautions

  • Blood dyscrasias: Monitor blood counts, especially in elderly
  • Agranulocytosis: Rare but serious risk
  • Suicidal thoughts: Monitor especially in young adults
  • Seizure risk: Use caution in patients with seizure history
  • Cardiac effects: Monitor in patients with cardiac disease
  • Liver function: Monitor hepatic function

Drug Interactions

  • MAOIs: Contraindicated – allow 14-day washout
  • CNS depressants: Enhanced sedation
  • Alcohol: Increased CNS depression
  • Warfarin: Monitor INR
  • Phenytoin: May affect levels

Adverse Reactions

Common:

  • Drowsiness, dizziness, dry mouth, weight gain

Serious:

  • Blood dyscrasias, agranulocytosis, seizures

Less Common:

  • Orthostatic hypotension, edema, arthralgia

Special Populations

  • Availability: Not available in United States
  • Pregnancy: Use only if benefits outweigh risks
  • Elderly: Lower doses, monitor blood counts closely
  • Hepatic impairment: Contraindicated in severe liver disease
  • Renal impairment: Use with caution
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.